All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-10-02T07:57:50.000Z

Evidence for favourable outcomes following outpatient auto-HCT treatment in MM

Oct 2, 2017
Share:

Bookmark this article

Autologous hematopoietic stem cell transplantation (auto-HCT) is common in patients with Multiple Myeloma (MM). Nina Shah, from the Hematology-Oncology Department, University of California San Francisco, and colleagues, performed a retrospective analysis of hospital charts for patients with MM undergoing auto-HCT. The aim of the study was to evaluate the differences in clinical characteristics and outcomes of inpatient versus outpatient treatment. The analysis considered patients with auto-HCT therapy between January 2008 and December 2012.

Key Findings

  • Patients enrolled in the study: n = 1046; inpatients = 669 vs outpatients = 377
  • Average patient age: inpatients vs outpatients = 58 (34–78) vs 62 (31–82)
  • Out-pts were significantly younger than inpatients: P < 0.001
  • Primary endpoints: unscheduled admissions, Treatment-Related Mortality (TRM), Grade 2–4 Adverse Events (AEs) and average cost of auto-HCT
  • Secondary endpoints: Overall Response Rates (ORR), Progression-Free Survival (PFS) and Overall Survival (OS)
  • Treatment-related mortality: inpatients vs outpatients = 10 patients (1.5%) vs 1 patient (0.3%), P = 0.10
  • Complete Response (CR): inpatients vs outpatients = 89.5% vs 5%, P < 0.001
  • Two-year PFS: inpatients vs outpatients = 50% vs 60%, HR = 0.7, 95% CI (0.6–0.9), P = 0.005
  • Two-year OS: inpatients vs outpatients = 77% vs 83%, HR = 0.6, 95% CI (0.4–0.9), P = 0.01
  • Average cost of transplant: inpatients vs outpatients = US$416,154 vs US$292,572

Safety

  • Non-hematologic Adverse Events (AEs):
    • Grade 2–5: inpatients vs outpatients = 552 (83%) vs 277 (73%)
  • 55% outpatients required hospital admission within 30 days of stem cell infusion; 42% due to neutropenic fever
  • Neutropenic fever: inpatients vs outpatients = 381 vs 154, P < 0.001

 

Conclusion

The outpatient group had a lower incidence of AEs and better PFS and OS. The authors suggested that these findings can be attributed to the more favorable baseline characteristics of the outpatient group, as they were younger, had a less advanced disease and fewer co-morbidities. Although a high number of outpatients required hospital admission (80%), they had fewer AEs and there was no significant difference between the two groups for treatment-related mortality.

This, therefore, suggests that the outpatient setting for auto-HCT can be carried out safely, with further study required to fully evaluate symptoms and quality of life for patients in this group. It must also be noted that this study was limited to some extent by patient bias, and future comparisons would need to be carried out using patients with more closely related baseline characteristics. However, this provides positive news for patients, for whom outpatient experiences are often viewed more favorably, and hospital trusts, as they would benefit from reduced overall treatment costs. However, patients need to be assessed on an individual basis.

  1. Shah N. et al. In-patient versus out-patient autologous hematopoietic stem cell transplantation for multiple myeloma. European Journal of Haematology. 2017 Sep 12. DOI: 10.1111/ejh.12970. [Epub ahead of print]

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox